Biopharmaceuticals Market Overview
The biopharmaceutical market size was at $485 million in 2025 and is projected to reach $951 million by 2035, at a CAGR of 6.5% from 2026 to 2035.
Biopharmaceuticals are large and complex molecular drugs that are mainly obtained from proteins and nucleic acids of living organisms, such as microorganisms and animal cells, also known as transgenic organisms. These drugs are obtained using biotechnology and have high therapeutic value. Biopharmaceuticals are also known as biologics and biotech drugs and are usually administered by intravenous, subcutaneous, or intramuscular injections and are more efficient than conventional small-molecule drugs.
Biopharmaceuticals Market Overview
| Metrics | Details |
| Market CAGR | 6.5% |
| Segments Covered | By Type, By Application, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Know More Insights - Download Sample
Biopharmaceuticals Market Dynamics
The growth of the global biopharmaceuticals market is driven by the increase in the elderly population, surge in prevalence of chronic diseases such as cancer and diabetes, increase in obesity and sedentary lifestyle among the population and growing acceptance for biopharmaceuticals due to their ability to treat previously untreatable diseases.
Increasing acceptance and huge market demand for biopharmaceuticals will drive the market growth
The efficacy and safety of biopharmaceutical products, combined with their ability to address previously untreatable conditions, allows pharma companies to command high prices for innovative drugs. Strong demand has driven significant profits, despite the high cost of goods sold. Investing in biotech R&D has yielded better returns than the pharma-industry average. The current biologics-development pipeline supports an outlook of continued healthy growth. There are currently more than 1,500 biomolecules undergoing clinical trials, and the success rate for biologics has so far been over twice that of small-molecule products, with 13 percent of biopharma products that enter the Phase I trial stage going on to launch. The success of the clinical pipeline will lead to an unprecedented number of new molecule launches, rising from a handful a few years ago to 10 to 15 annually, as biopharma products make up an increasing share of new approvals from the US Food and Drug Administration in the future. A further steep increase is to be expected as multiple players begin to receive approval for the production of biosimilars after 2015.
Biopharmaceuticals looks poised to transform the industry once more, as increasing understanding of the interaction between drugs and the genetic makeup of patients helps to improve the targeting of therapies. Combined with robust, low-cost genetic profiling, this knowledge will improve treatment outcomes and serve to accelerate and improve the outcomes of clinical trials, helping to reduce the cost of drug development.
High costs associated with and a strict regulatory framework are likely to hamper the market growth
However, high costs associated with drug development and their threat of failure, challenging development process, and strict regulatory framework are going to restrain the market in the forecast period.
Generally, the development of a biopharmaceutical product takes around 5 to 9 years and costs over $ 100 million. The regulatory framework plays a major role in deriving incentives for investment and establishing sufficient quality and safety for biomedical products. The WHO has set strict approval standards for biopharmaceuticals. These factors will hamper the market growth in the forecast period.
COVID-19 Impact Analysis
The ongoing COVID-19 pandemic globally is expected to have a significant impact on the biopharmaceutical market. Most of the biopharmaceutical companies are striving extensively for the development of vaccines against the SARS-CoV2 virus. Some of the candidates are traditional-type vaccines such as inactivated and attenuated products; however, most of the vaccine candidates being developed are advanced DNA, RNA, and protein subunit vaccines. This factor is expected to boost the growth of the biopharmaceuticals market over the pandemic. However, the clinical and regulatory procedures for drug candidates of other indications may witness a slow pace due to the shifting priorities of the healthcare system to reduce the infections to clinical trial patients.
Biopharmaceuticals Market Segmentation
The monoclonal antibody segment is expected to grow at the fastest CAGR during the forecast period (2026-2035)
Monoclonal antibodies is the emerging technology that is identical to immune cells and represents a copy of the unique parent cell. The successful use of monoclonal antibodies and antibody derivatives in therapeutics is the major driver for the rapid growth of the studied segment. The therapeutic applications of monoclonal antibodies include in the areas of cancer, rheumatoid arthritis, multiple sclerosis, and cardiovascular diseases, among others. The growing FDA approvals and new product launches for various indications are expected to drive the segment. For instance, in October 2019, Novartis received the FDA approval for its Beovu (brolucizumab) injection, also known as RTH258, for the treatment of wet age-related macular degeneration (AMD). In March 2019, the US FDA approved Pfizer’s oncology biosimilar, TRAZIMERA, which is a monoclonal antibody biosimilar to the originator biologic medicine, Herceptin. Thus, owing to the aforementioned factors, the monoclonal antibodies segment is anticipated to witness significant growth over the forecast period.
Biopharmaceuticals Market Geographical Share
The North American region holds the largest market share of the global biopharmaceuticals market
North America accounts for the largest share in the global biopharmaceuticals market in 2025 and is expected to remain dominant over the forecast period. The growing burden of chronic disease and increasing investments in research and development activities in the United States are the major factors driving the biopharmaceuticals market in North America. The United States has been recognized as the innovation capital of the world for life sciences, and it is involved in global capital investments in the early stages of biopharmaceutical companies.
According to Globocan 2020, the estimated incidence of cancer cases in the United States accounted for 2,281,658, with 612,390 deaths, in 2020. The high incidence of cancer surges the demand for effective therapeutics, and thus, drives the studied market. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), in 2018, more than 4.7 million people worked in the US biopharmaceutical industry across a broad spectrum of occupations, including scientific research, technical support, and manufacturing. Additionally, in March 2020, Thermo Fisher Scientific Inc. invested nearly USD 475 million as a biopharma investment in the expansion of biologics, cell and gene therapy, and drug product development and to increase its commercial capabilities globally. Similarly, in January 2020, Eli Lilly and Company entered an agreement to acquire Dermira, a biopharmaceutical company. This acquisition aids in the expansion of the company's biopharmaceutical portfolio with the addition of Dermira's lebrikizumab, an IL-13 antibody that is intended for use in the treatment of moderate-to-severe atopic dermatitis. Thus, the given factors, are expected to drive the market in North America.
Biopharmaceuticals Companies and Competitive Landscape
The biopharmaceuticals market is moderately competitive, with the presence of local as well as global companies. Some of the key players that are contributing to the growth of the market include Abbvie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson, Novartis AG, Novo Nordisk AS, Pfizer Inc., GlaxoSmithKline PLC, and F. Hoffmann-La Roche AG, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Biopharmaceuticals Market globally. For instance, in July 2021, Takeda Pharmaceutical and Frazier Healthcare Partners partnered to launch a biopharmaceutical company named HilleVax to develop and market Takeda’s norovirus vaccine candidate, HIL-214.
Amgen Inc.
Overview:
Amgen Inc. is an independent biotechnology company that discovers, develops, manufactures, and markets medicines for grievous illnesses.
Product Portfolio:
BEHIND MVASI: MVASI® is approved to treat metastatic colorectal cancer (mCRC) for First- or second-line treatment in combination with intravenous fluorouracil-based chemotherapy.
Recent Developments in the Biopharmaceutical Market
- GLP-1 and Next-Generation Obesity Biologics Transform Biopharma Investments
The success of GLP-1 therapies from companies such as Novo Nordisk and Eli Lilly and Company has accelerated investment into metabolic disease biologics, peptide therapeutics, and next-generation obesity treatments. Biopharmaceutical pipelines are increasingly centered around chronic disease management and precision medicine. - AI-Driven Drug Discovery Becomes Mainstream Across Biopharma R&D
Biopharmaceutical companies are rapidly integrating AI and generative biology platforms into drug discovery, target identification, and clinical trial optimization. AI-assisted biologics development is reducing early-stage R&D timelines and improving candidate selection efficiency across the industry. - Cell and Gene Therapy Manufacturing Capacity Expands Globally
Major biopharmaceutical manufacturers are increasing investments in cell therapy, gene editing, and mRNA manufacturing infrastructure. The market is witnessing rapid expansion of GMP biologics facilities to support personalized medicine, oncology therapies, and rare disease treatment pipelines. - Biosimilars and Biologics Competition Intensify Worldwide
Patent expirations for major biologics are accelerating biosimilar launches across oncology, immunology, and autoimmune disease segments. Companies are focusing on cost-effective biologic alternatives while maintaining high efficacy and regulatory compliance standards. - Biopharma Supply Chains Shift Toward Regionalized and Resilient Manufacturing
Following supply chain disruptions experienced in recent years, biopharmaceutical companies are diversifying manufacturing operations, increasing local production capabilities, and investing in flexible bioprocessing technologies to improve resilience and reduce dependency on single-region sourcing.
